PMID: 11924912Apr 2, 2002Paper

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications

Journal of Immunotherapy
Steven P TreonKenneth C Anderson

Abstract

Clonotypic B cells circulating in patients with multiple myeloma (MM) express CD20, and it has been suggested that these cells may be clonogenic. Furthermore, 20% of patients with MM express CD20 on their bone marrow plasma cells (BMPCs). Therefore, the authors began a phase II clinical study to determine the activity of the anti-CD20 monoclonal antibody rituximab in MM patients. Nineteen previously treated MM patients received 375 mg/m2 rituximab per week for 4 weeks. Three months after initiation of treatment, patients were assessed for response and received a second course of therapy if their disease was stable (SD) or they achieved a partial response (PR). Six of 19 (32%) patients had either a PR (n = 1) or SD (n = 5), with a median time to treatment failure of 5.5 months (mean, 10.3 months; range, 3-27+ months). All six patients who had a PR or SD had CD20+ BMPC. Overall, rituximab therapy was well tolerated. Because most patients with MM poorly express CD20 on their BMPCs, the authors evaluated agents for their ability to induce CD20 expression and thereby facilitate rituximab binding on MM cells. These studies show that interferon-gamma (IFN-y) induced CD20 expression on MM BMPCs, MM B cells, and healthy donor BMPCs. In ...Continue Reading

References

Apr 1, 1991·European Journal of Haematology·H Jernberg-WiklundK Nilsson
May 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P H DriggersK Ozato
Feb 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vadhan-RajS E Krown
Jul 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KurzrockJ U Gutterman
Mar 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A E MaluishR G Steis
Sep 1, 1988·European Journal of Cancer & Clinical Oncology·S EinhornR Lewensohn
Jan 1, 1985·Cancer Immunology, Immunotherapy : CII·K A FoonR B Herberman
May 9, 1995·Proceedings of the National Academy of Sciences of the United States of America·K KarmannJ S Pober
Nov 5, 1997·Nature Genetics·S IidaR Dalla-Favera
Dec 17, 1997·Biochemical and Biophysical Research Communications·P GutiérrezJ León
Mar 27, 1998·Current Opinion in Hematology·S P Treon, K C Anderson
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Aug 26, 1998·Journal of Clinical Pathology·L GinaldiD Catovsky
May 8, 1999·British Journal of Haematology·T RasmussenH E Johnsen

❮ Previous
Next ❯

Citations

Oct 10, 2009·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Richard J Jones
Dec 2, 2010·Clinical Rheumatology·Annette F JanssonVeit Grote
Jan 5, 2011·Apoptosis : an International Journal on Programmed Cell Death·Bo MuYu-quan Wei
Aug 20, 2011·Leukemia·N W C J van de DonkH M Lokhorst
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Deepak GuptaKenneth C Anderson
Dec 13, 2006·TheScientificWorldJournal·Janice Jin HwangKenneth C Anderson
Jan 11, 2005·British Journal of Haematology·Toshiaki HayashiKenneth C Anderson
Dec 23, 2004·European Journal of Haematology·Taiji YokoteToshiaki Hanafusa
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jing YangQing Yi
Nov 25, 2003·Blood·William MatsuiRichard J Jones
Sep 10, 2005·Blood·Carol Ann HuffRichard J Jones
Sep 4, 2013·Immunotherapy·Frederick L LockeMohamed A Kharfan-Dabaja
Aug 27, 2009·Biologics : Targets & Therapy·Beate Hauptrock, Georg Hess
Mar 18, 2010·Leukemia & Lymphoma·Linda M PilarskiAndrew R Belch
Jun 7, 2006·Leukemia & Lymphoma·Thierry AlcindorThomas E Witzig
Mar 16, 2007·Expert Opinion on Emerging Drugs·Irene M GhobrialPaul Richardson
Apr 7, 2010·Expert Opinion on Biological Therapy·Andrea Di BernardoClaudio Tripodo
Dec 5, 2008·Expert Opinion on Investigational Drugs·Tomer MarkRuben Niesvizky
Feb 18, 2012·American Journal of Clinical Pathology·Elisa CannizzoFrederic Preffer
Oct 23, 2009·American Journal of Clinical Pathology·Ritu GuptaParesh Jain
Jan 15, 2011·Seminars in Hematology·Constance M Yuan, Maryalice Stetler-Stevenson
Nov 11, 2008·Leukemia Research·Yuji HirataToshiaki Hanafusa
Sep 24, 2008·Cancer Letters·Nilanjan Ghosh, William Matsui
Dec 12, 2007·Best Practice & Research. Clinical Haematology·Constantine S MitsiadesPaul G Richardson
Nov 13, 2007·Hematology/oncology Clinics of North America·Teru Hideshima, Kenneth C Anderson
Dec 7, 2007·Free Radical Biology & Medicine·Damodar GuptaRoger M Macklis
Mar 27, 2007·The Journal of Pediatrics·Lisa B GiulinoUNKNOWN Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network
Mar 24, 2007·Experimental Hematology·Kenneth C Anderson
Jul 15, 2015·Critical Reviews in Oncology/hematology·Ayed O AyedJan S Moreb
Jul 9, 2003·Immunological Reviews·Teru HideshimaKenneth C Anderson
Mar 11, 2004·Pediatric Transplantation·Mark D Pescovitz
Mar 1, 2007·Transplant International : Official Journal of the European Society for Organ Transplantation·Dirk R J KuypersYves Vanrenterghem
Mar 6, 2008·British Journal of Haematology·Prashant KapoorPhilip R Greipp
Oct 3, 2006·British Journal of Haematology·Silvie CloosenGerard M J Bos
Mar 20, 2013·European Journal of Haematology·Alessandro AllegraCaterina Musolino
Oct 12, 2013·British Journal of Haematology·Roman HajekHana Svachova

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.